Simone L. Cree
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simone L. Cree has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Anna P. Pilbrow
Christchurch Heart Institute, Department of Medicine, University of Otago
1 shared publication- Kim N. T. Ton
University of Otago
1 shared publication - Lisa K. Stamp
Department of Medicine University of Otago Christchurch Christchurch New Zealand
1 shared publication - Martin Alexander Kennedy
Department of Pathology and Molecular Medicine, University of Otago, Christchurch, New Zealand
1 shared publication Moritz Lassé
Department of Medicine, and Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf
1 shared publicationSabine J. Gronert-Sum
JSI medical systems GmbH
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 13, 2014518
Editorial: Advancements in biomarker genetics: insights from the genomics era
The Research Topic "Advancements in Biomarker Genetics: Insights from the Genomics Era" brings together eight contributions illustrating this transition. Collectively, these studies span genetic and epigenetic biomarkers, long-read sequencing, pharmacogenomics, metabolic biomarkers, circulating bacterial DNA, and population-specific genetic associations. Despite their diverse clinical settings, they converge on a common principle: biomarker interpretation increasingly requires consideration of genomic diversity within and between populations. This is particularly evident in the contribution by van der Laan et al., "Nanopore sequencing enables combined detection of USP7 variants and a known Hao-Fountain syndrome episignature". Using Oxford Nanopore long-read sequencing in 5 individuals with Hao-Fountain syndrome, the authors identified pathogenic USP7 single-nucleotide variants, structural deletions and a characteristic DNA methylation episignature. The study demonstrates the potential for a single sequencing platform to integrate genomic and epigenomic information that has traditionally required separate assays. Such approaches point towards a future in which several different types of markers can be measured a single assay, potentially leading to better risk estimates and reduced cost.The epigenetic dimension of biomarker discovery is developed further by Munns et al., "Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health". Their review highlights the potential of DNA methylation signatures for risk prediction and monitoring in type 2 diabetes, while identifying important limitations in reproducibility, genome coverage and population representation. Importantly, they argue for sequencing-based methylation profiling, larger longitudinal cohorts, and the meaningful inclusion of genetically diverse and Indigenous populations. This contribution emphasizes that technological innovation and health equity must progress together if precision medicine is to deliver broadly applicable benefits.The importance of population context is also evident in Saed et al., "Association between CTLA-4 gene polymorphisms and Type 1 diabetes in Kurdish patients". In this preliminary study, the G allele of the CTLA-4 +49 A>G (rs231775) variant was associated with increased susceptibility to type 1 diabetes in a Kurdish population in Iraq (52 patients, 21 healthy controls), whereas the -318 C>T variant was not. These polymorphisms may influence susceptibility to type 1 diabetes by altering expression and cell-surface availability of CTLA-4, an immune checkpoint receptor that acts as a brake on T-cell activation, thereby potentially permitting enhanced autoreactive Tcell-mediated destruction of pancreatic β-cells. Although this finding requires confirmation in larger cohorts, the study illustrates the value of extending genetic association research to populations historically underrepresented in genomic studies.Population-specific evaluation is equally relevant to conventional biochemical biomarkers. In their study "Associations between glycated albumin and current measures of glycaemic control in Saudi adults", Bahijri et al. found that glycated albumin correlated with established measures of glycaemic status and distinguished normoglycaemia from intermediate hyperglycaemia and diabetes in 132 adults from Saudi Arabia. Their findings support further evaluation of glycated albumin as an alternative or complementary glycaemic biomarker while emphasizing the need to establish appropriate ranges in the population in which it will be used.The relationship between genotype and clinical phenotype is explored from another perspective by Ji et al., "Correlation of UGT1A1 genotypes with newborn hyperbilirubinemia using newborn genetic screening". Among 115 newborns undergoing genetic screening, biallelic or multi-allelic UGT1A1 variants were associated with mildly higher transcutaneous bilirubin concentrations at 6 weeks, suggesting slower postnatal bilirubin clearance. However, clinically significant neonatal hyperbilirubinemia was uncommon and did not differ significantly between variant carriers and controls. The study therefore illustrates that the link between detectable genotype-phenotype associations and prediction of clinically significant variants is not always straight forward in genomic biomarker research.The need for similar caution is reinforced by Wang et al. in their study "Association between the TNF-α-308G/A and TNF-α-238G/A polymorphisms and systemic lupus erythematosus susceptibility: an updated meta-analysis". Although conventional meta-analysis of 53 studies identified several statistically significant associations, evaluation using prediction intervals and Bayesian false-discovery probability indicated that these were less-credible positive findings. This work provides a timely reminder that statistical association alone is insufficient for biomarker discovery; reproducibility, effect size, heterogeneity, population structure, and the probability of false-positive findings must all be considered. Genomic information may also help personalize treatment. In "Gene polymorphisms associated with immunosuppressant adverse effects in systemic lupus erythematosus: a narrative review", Hamdani et al., summarize variants associated with adverse effects from methotrexate, azathioprine, cyclophosphamide, and mycophenolate mofetil across 23 studies. Their review illustrates the potential of pharmacogenomic biomarkers to move precision medicine beyond disease susceptibility towards drug selection, dosage optimization, and avoidance of treatment toxicity.Finally, in their review "Circulating bacterial DNA in cardiovascular disease", Appleby and Purcell broaden the genomic biomarker concept beyond the human genome. They highlight circulating bacterial DNA as a potential diagnostic and prognostic marker in cardiovascular disease and...
- 16 October 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 13, 2014518
Open AccessEditorial: Advancements in biomarker genetics: insights from the genomics era
The Research Topic "Advancements in Biomarker Genetics: Insights from the Genomics Era" brings together eight contributions illustrating this transition. Collectively, these studies span genetic and epigenetic biomarkers, long-read sequencing, pharmacogenomics, metabolic biomarkers, circulating bacterial DNA, and population-specific genetic associations. Despite their diverse clinical settings, they converge on a common principle: biomarker interpretation increasingly requires consideration of genomic diversity within and between populations. This is particularly evident in the contribution by van der Laan et al., "Nanopore sequencing enables combined detection of USP7 variants and a known Hao-Fountain syndrome episignature". Using Oxford Nanopore long-read sequencing in 5 individuals with Hao-Fountain syndrome, the authors identified pathogenic USP7 single-nucleotide variants, structural deletions and a characteristic DNA methylation episignature. The study demonstrates the potential for a single sequencing platform to integrate genomic and epigenomic information that has traditionally required separate assays. Such approaches point towards a future in which several different types of markers can be measured a single assay, potentially leading to better risk estimates and reduced cost.The epigenetic dimension of biomarker discovery is developed further by Munns et al., "Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health". Their review highlights the potential of DNA methylation signatures for risk prediction and monitoring in type 2 diabetes, while identifying important limitations in reproducibility, genome coverage and population representation. Importantly, they argue for sequencing-based methylation profiling, larger longitudinal cohorts, and the meaningful inclusion of genetically diverse and Indigenous populations. This contribution emphasizes that technological innovation and health equity must progress together if precision medicine is to deliver broadly applicable benefits.The importance of population context is also evident in Saed et al., "Association between CTLA-4 gene polymorphisms and Type 1 diabetes in Kurdish patients". In this preliminary study, the G allele of the CTLA-4 +49 A>G (rs231775) variant was associated with increased susceptibility to type 1 diabetes in a Kurdish population in Iraq (52 patients, 21 healthy controls), whereas the -318 C>T variant was not. These polymorphisms may influence susceptibility to type 1 diabetes by altering expression and cell-surface availability of CTLA-4, an immune checkpoint receptor that acts as a brake on T-cell activation, thereby potentially permitting enhanced autoreactive Tcell-mediated destruction of pancreatic β-cells. Although this finding requires confirmation in larger cohorts, the study illustrates the value of extending genetic association research to populations historically underrepresented in genomic studies.Population-specific evaluation is equally relevant to conventional biochemical biomarkers. In their study "Associations between glycated albumin and current measures of glycaemic control in Saudi adults", Bahijri et al. found that glycated albumin correlated with established measures of glycaemic status and distinguished normoglycaemia from intermediate hyperglycaemia and diabetes in 132 adults from Saudi Arabia. Their findings support further evaluation of glycated albumin as an alternative or complementary glycaemic biomarker while emphasizing the need to establish appropriate ranges in the population in which it will be used.The relationship between genotype and clinical phenotype is explored from another perspective by Ji et al., "Correlation of UGT1A1 genotypes with newborn hyperbilirubinemia using newborn genetic screening". Among 115 newborns undergoing genetic screening, biallelic or multi-allelic UGT1A1 variants were associated with mildly higher transcutaneous bilirubin concentrations at 6 weeks, suggesting slower postnatal bilirubin clearance. However, clinically significant neonatal hyperbilirubinemia was uncommon and did not differ significantly between variant carriers and controls. The study therefore illustrates that the link between detectable genotype-phenotype associations and prediction of clinically significant variants is not always straight forward in genomic biomarker research.The need for similar caution is reinforced by Wang et al. in their study "Association between the TNF-α-308G/A and TNF-α-238G/A polymorphisms and systemic lupus erythematosus susceptibility: an updated meta-analysis". Although conventional meta-analysis of 53 studies identified several statistically significant associations, evaluation using prediction intervals and Bayesian false-discovery probability indicated that these were less-credible positive findings. This work provides a timely reminder that statistical association alone is insufficient for biomarker discovery; reproducibility, effect size, heterogeneity, population structure, and the probability of false-positive findings must all be considered. Genomic information may also help personalize treatment. In "Gene polymorphisms associated with immunosuppressant adverse effects in systemic lupus erythematosus: a narrative review", Hamdani et al., summarize variants associated with adverse effects from methotrexate, azathioprine, cyclophosphamide, and mycophenolate mofetil across 23 studies. Their review illustrates the potential of pharmacogenomic biomarkers to move precision medicine beyond disease susceptibility towards drug selection, dosage optimization, and avoidance of treatment toxicity.Finally, in their review "Circulating bacterial DNA in cardiovascular disease", Appleby and Purcell broaden the genomic biomarker concept beyond the human genome. They highlight circulating bacterial DNA as a potential diagnostic and prognostic marker in cardiovascular disease and...
- Open Access
Multiplexed nanopore sequencing of HLA-B locus in Māori and Polynesian samples
The human leukocyte antigen (HLA) system is a gene family that encodes the human major histocompatibility complex (MHC). HLA-B is the most polymorphic gene in the MHC class I region, comprised of 4,765 HLA-B alleles (IPD-IMGT/HLA Database Release 3.28). Many HLA-B alleles have been associated with adverse drug reactions and disease risks, and we are interested in developing efficient methods for analysis of HLA alleles in this context. Here we describe an approach to HLA-B typing using multiplexed next generation sequencing on the MinION™ nanopore sequencer (Oxford Nanopore Technologies), combined with data analysis with the SeqNext-HLA software package (JSI Medical Systems GmbH, Ettenheim, Germany). The nanopore sequencer offers the advantages of long-read capability and single molecule reads, which can facilitate effective haplotyping. We developed this method using reference samples of known HLA-B type as well as individuals of New Zealand Māori or Pacific Island (Polynesian) descent, because HLA-B diversity in these populations is not well understood. We demonstrate here that nanopore sequencing of barcoded, pooled, 943 bp polymerase chain reaction (PCR) amplicons of 49 DNA samples, on one R9.4 flowcell (Oxford Nanopore Technologies), generated ample read depth for all samples. Sequence analysis using SeqNext-HLA software assigned HLA-B alleles to all samples at high-resolution with very little ambiguity. Our PCR-based next generation sequencing method is a scaleable and efficient approach for genotyping HLA-B and potentially any other HLA locus. Finally, we report our findings on HLA-B genotypes of this cohort, which adds to our understanding of HLA-B allele frequencies among Māori and Polynesian people.
Open AccessMultiplexed nanopore sequencing of HLA-B locus in Māori and Polynesian samples
The human leukocyte antigen (HLA) system is a gene family that encodes the human major histocompatibility complex (MHC). HLA-B is the most polymorphic gene in the MHC class I region, comprised of 4,765 HLA-B alleles (IPD-IMGT/HLA Database Release 3.28). Many HLA-B alleles have been associated with adverse drug reactions and disease risks, and we are interested in developing efficient methods for analysis of HLA alleles in this context. Here we describe an approach to HLA-B typing using multiplexed next generation sequencing on the MinION™ nanopore sequencer (Oxford Nanopore Technologies), combined with data analysis with the SeqNext-HLA software package (JSI Medical Systems GmbH, Ettenheim, Germany). The nanopore sequencer offers the advantages of long-read capability and single molecule reads, which can facilitate effective haplotyping. We developed this method using reference samples of known HLA-B type as well as individuals of New Zealand Māori or Pacific Island (Polynesian) descent, because HLA-B diversity in these populations is not well understood. We demonstrate here that nanopore sequencing of barcoded, pooled, 943 bp polymerase chain reaction (PCR) amplicons of 49 DNA samples, on one R9.4 flowcell (Oxford Nanopore Technologies), generated ample read depth for all samples. Sequence analysis using SeqNext-HLA software assigned HLA-B alleles to all samples at high-resolution with very little ambiguity. Our PCR-based next generation sequencing method is a scaleable and efficient approach for genotyping HLA-B and potentially any other HLA locus. Finally, we report our findings on HLA-B genotypes of this cohort, which adds to our understanding of HLA-B allele frequencies among Māori and Polynesian people.